Polymyxin B / Colistin
Last-line polymyxin antibiotics for MDR gram-negatives.
What it's for
Last-line polymyxin antibiotics for MDR gram-negatives.
What it's for
Polymyxin B and colistin (polymyxin E) are cyclic cationic peptide antibiotics. They treat serious infections due to susceptible multidrug-resistant gram-negative bacteria when alternatives are limited.
What it does for the body
They treat serious infections due to susceptible multidrug-resistant gram-negative bacteria when alternatives are limited. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
They bind LPS (a building block of some bacterial outer membranes) and disrupt outer/inner membranes of gram-negative bacteria, causing cell death. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Polymyxin B / Colistin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Immune research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Polymyxin B / Colistin — FDA.gov search
- ClinicalTrials.gov search: Polymyxin B / Colistin — U.S. clinical trials registry
- Drugs@FDA search: Polymyxin B / Colistin — FDA drug database (if approved)
- PubMed search: Polymyxin B / Colistin — NCBI PubMed
- PubMed Central search: Polymyxin B / Colistin — NCBI PMC